While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types1.

These figures demonstrate that the development of highly effective targeted therapeutics and immunotherapies is more important than ever, despite the astonishing rate of progress.

In the last few years, immunotherapies like immune checkpoint inhibitors, vaccines and cell and gene therapies have revolutionised the treatment of cancer, and targeted drugs like monoclonal antibodies (mAbs), poly-ADP ribose polymerase (PARP) inhibitors and targeted protein degraders are also playing an important role.

This 24-page eBook sponsored by Sino Biological explores the latest innovations in cancer therapeutics and where we can expect the greatest breakthroughs in the future.

Download this exclusive eBook to learn more about:

  • The opportunities and advances in cancer research
  • Why liquid biopsies are important in precision medicine trials for cancer
  • How genetic tuning willtransform the reach for CAR-T therapies
  • The latest developments in breast cancer therapy

References

  1. https://cancerprogressreport.aacr.org/progress/